Inhaler choice in primary practice

European Respiratory Review

Volumn 14, Issue 96, 2005, Pages 117-122

  Chapman, K R ^a   Voshaar, T H ^b   Virchow, J C ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Krankenhaus Bethanien   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Deposition; Dry powder inhaler; Inhaler technique; Pressurised metered dose inhaler

Indexed keywords

ALGORITHM; ASTHMA; BREATH ACTUATED PRESSURIZED METERED DOSE INHALER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONFERENCE PAPER; HEALTH CARE AVAILABILITY; HEALTH PERSONNEL ATTITUDE; HUMAN; INHALER; MEDICAL DECISION MAKING; MEDICAL PRACTICE; METERED DOSE INHALER; NEBULIZER; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT GUIDANCE; PATIENT MONITORING; PATIENT SELECTION; POWDER INHALER; PRESSURIZED METERED DOSE INHALER; PRIMARY HEALTH CARE; SOFT MIST INHALER; TECHNIQUE; TREATMENT OUTCOME;

EID: 29744470928     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.05.00009607     Document Type: Conference Paper

References (38)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-1504.
2. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
3. Sheffer AL, Bousquet J, Busse WW, et al. International consensus report on diagnosis and mangement of asthma. Publication #92-3091. Bethesda, U.S. Department of Health and Human Services, 1992.
4. Chapman KR, Bourbeau J, Ranee L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003; 97: Suppl. C, S23-S31.
5. Chapman KR, Ernst P, Grenville A, Dewland P, Zimmerman S. Control of asthma in Canada: failure to achieve guideline targets. Can Respir J 2001; 8: Suppl. A, 35A-40A.
6. Chapman KR, Boulet LP, Rea R. Physician self-audit of asthma control in primary practice: the implications for implementation of guidelines. Am J Respir Crit Care Med 2004; 169: A362.
7. Hesselink AE, Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand J Prim Health Care 2001; 19: 255-260.
8. Coady TJ, Davies HJ, Barnes P. Evaluation of a breath actuated pressurized aerosol. Clin Allergy 1976; 6: 1-6.
9. Epstein SW, Manning CP, Ashley MJ, Corey PN. Survey of the clinical use of pressurized aerosol inhalers. Can Med Assoc J 1979; 120: 813-816.
10. Coady TJ, Stewart CJ, Davies HJ. Synchronization of bronchodilator release. Practitioner 1976; 217: 273-275.
11. Paterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients. BMJ 1976; 1: 76-77.
12. De Boeck K, Alifier M, Warnier G. Is the correct use of a dry powder inhaler (Turbohaler) age dependent? J Allergy Clin Immunol 1999; 103: 763-767.
13. Hansen OR, Pedersen S. Optimal inhalation technique with terbutaline Turbuhaler. Eur Respir J 1989; 2: 637-639.
14. Kamps AW, van Ewijk B, Roorda RJ, Brand PL. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000; 29: 39-42.
15. Epstein SW, Maidenberg A, Hallett D, Khan K, Chapman KR. Patient handling of a dry-powder inhaler in clinical practice. Chest 2001; 120: 1480-1484.
16. Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev 2005; 14: 109-116.
17. Kelling JS, Strohl KP, Smith RL, Altose MD. Physician knowledge in the use of canister nebulizers. Chest 1983; 83: 612-614.
18. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 1994; 105: 111-116.
19. Kesten S, Zive K, Chapman KR. Pharmacist knowledge and ability to use inhaled medication delivery systems. Chest 1993; 104: 1737-1742.
20. Jackevicius CA, Chapman KR. Inhaler education for hospital-based pharmacists: how much is required? Can Respir J 1999; 6: 237-244.
21. Nsour WM, Alldred A, Corrado J, Chrystyn H. Measurement of peak inhalation rates with an in-check meter to identify an elderly patient's ability to use a turbuhaler. Respir Med 2001; 95: 965-968.
22. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev 2005; 14: 102-108.
23. Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994; 150: 1256-1261.
24. Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Mem Med 1988; 148: 1949-1952.
25. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 1993; 104: 1332-1337.
26. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335-371.
27. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004; 283: 1-9.
28. Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med 1999; 12: Suppl. 1, S25-S31.
29. Hodder R, Pavia D, Dewberry H, et al. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat® Soft Mist™ inhaler. Respir Med 2005; 99: 1087-1095.
30. Voshaar T, Hausen T, Kardos P, et al. [Inhalation therapy with Respimat soft inhaler in patients with COPD and asthma]. Pneumologie 2005; 59: 25-32.
31. Koehler D, Pavia D, Dewberry H, Hodder R. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat® Soft Mist™ inhaler: results of phase II single-dose crossover studies. Respiration 2004; 71: 469-476.
32. Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med 2004; 98: 387-397.
33. Vincken W, Bantje T, Middle MV, Gerken F, Moonen D. Long-term efficacy and safety of ipratropium bromide plus fenoterol via Respimat® Soft Mist™ Inhaler (SMI) versus a pressurised metered-dose inhaler in asthma. Clin Drug Invest 2004; 24: 17-28.
34. von Berg A, Jeena PM, Soemantri PA, et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs. a conventional metered-dose inhaler plus spacer in children with asthma. Pediatr Pulmonol 2004; 37: 264-272.
35. van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999; 14: 1034-1037.
36. Voshaar T, App EM, Berdel D, et al. [Recommendations for the choice of inhalatory systems for drug prescription]. Pneumologie 2001; 55: 579-586.
37. Virchow JC Jr, Kroegel C, Matthys H. What is on the horizon? Clin Pharmacokinet 1994; 27: 85-93.
38. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246-251.